Results 101 to 110 of about 49,244 (195)

Peginterferon-?2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose

, 2004
BACKGROUND: Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C. OBJECTIVE: To assess the efficacy and safety of 24 or 48 weeks
Ramadori, Giuliano, Balan, Vijayan, Diago, Moises, JrMorgan, Timothy R., Bodenheimer, Henry, Sette, Hoel, Lin, Amy, Marcellin, Patrick, Ackrill, Andrew M., Hadziyannis, Stephanos J., Rizzetto, Mario, Pockros, Paul J., JrBernstein, David, Zeuzem, Stefan   +13 more
core   +1 more source

Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia

, 2003
Background: Ribavirin administration for chronic hepatitis C is associated with the development of haemolytic anaemia, which affects treatment efficacy and tolerability.
UTILI, Riccardo, RUGGIERO G., MARRONE, Aldo, SAVIANO D, DURANTE MANGONI, Emanuele, DEL VECCHIO C   +5 more
core  

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy

BMC Infectious Diseases
Background Globally, 80 million people are suffering from chronic Hepatitis C virus (HCV) infection. Sofosbuvir ribavirin-based anti-HCV therapy is associated with anemia and other adverse effects.
Sameen Amjed, Hafiz Ghulam Murtaza Saleem, Sajjad Ullah, Shahzad Latif, Shabana, Junaid Jafar, Ahmad Bilal Waqar   +6 more
doaj   +1 more source

Selection for West Nile virus populations with decreased susceptibility to ribavirin.

, 2015
A. Ribavirin susceptibility, measured as mean log10 pfu/ml reduction in viral titer +/- SD resulting from 50uM ribavirin treatment for 72h on Hela cell culture relative to untreated controls, following passage of parallel series of ribavirin-treated WNV ...
Jamie J. Arnold (120696), Laura D. Kramer (319003), Craig E. Cameron (120731), Alexander T. Ciota (319001), Sara B. Griesemer (272402), Alex J. Lugo (761323), Greta A. Van Slyke (761322), Ibrahim M. Moustafa (761324)   +7 more
core   +1 more source

Biotechnological method of the synthesis of new ribavirin structural analogs.

, 2008
Modern effective biotechnological method of the synthesis of new analogues of 1-β-D-ribifuranozyl-1,2,4- triazole-3-carboxamide (ribavirin) from 3-amino-1,2,4-triazole was developed.
V. I. Shvets, I. V. Fateev, I. D. Konstantinova   +2 more
core  

Induction of ERK1/2 phosphorylation by ribavirin correlated with p53 phosphorylation and suppression of HCV replication.

, 2012
(A) Dose-dependent phosphorylation of ERK1/2 by ribavirin. HepG2 cells were treated for 24 h with the indicated doses of ribavirin. (B) The association of ribavirin-induced ERK1/2 phosphorylation with p53 phosphorylation in a time-course analysis.
Wei-Liang Liu (138279), Hurng-Yi Wang (130558), Ming-Yang Lai (138312), Chih-Chiang Wang (138296), Hui-Ling Chen (138302), Ding-Shinn Chen (53409), Wen-Cheng Su (138291), Hung-Chih Yang (138284), Wen-Hung Huang (138307)   +8 more
core   +1 more source

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis

Diseases
Background: There is still debate whether ribavirin should be added to direct-acting antivirals (DAAs) for the management of treatment-experienced individuals with non-genotype-1 hepatitis C.
Shahd Hamran, Amani A. Al-Rajhi, Kawthar Jasim, Majed A. Al-Theyab, Mohamed Elahtam, Mooza K. Al-Hail, Wadha Al-Fahaidi, Yaman A. Khamis, Yara Dweidri, Abdel-Naser Elzouki, Tawanda Chivese   +10 more
doaj   +1 more source

Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations

, 2011
BACKGROUND: Ribavirin is an essential component in the treatment of chronic hepatitis C (HCV) infection. Although ribavirin dose is weight-based, data in the literature suggest large between-patient variability in plasma ribavirin concentrations.
Drenth, J.P.H., Koopmans †, P.P., Hanneke W H A Huntjens-Fleuren, Ton S M Dofferhoff, Huntjens-Fleuren, H.W., Joost P H Drenth, Burger, D.M., David M Burger, Slavenburg, S., Clemens Richter, Corrien P W G M Verwey-Van Wissen, Verwey-van Wissen, C.P.W.G.M., Serena Slavenburg, Richter, C., Dofferhoff, T.S., Peter P Koopmans   +15 more
core   +1 more source

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis

Clinical and Experimental Gastroenterology, 2012
Eric Druyts1, Edward J Mills1,2, Jean Nachega3, Christopher O'Regan4, Curtis L Cooper51Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON,
O'Regan C, Nachega J, Mills EJ, Druyts E, Cooper CL   +4 more
doaj  

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

, 1998
AIMS: The primary objective of this study was to determine whether pharmacokinetic interactions occurred between interferon alpha-2b (IFN) and ribavirin in patients with chronic hepatitis C infections.
Bell, A., Lypnyj, D., Walters, K., Khakoo, Salim I., Grellier, L., Dash, C., Flannery, B., Glue, P., Wells, B., Murray-Lyon, I., Dusheiko, G.M.   +10 more
core   +1 more source